Table 1 FDA approved therapeutic monoclonal antibodies for cancer therapy
From: Targeted drug delivery for cancer therapy: the other side of antibodies
Generic name | Proprietary name | Target | Technology | Isotype | Additional manipulations | Year FDA approved | Approved clinical indication |
|---|---|---|---|---|---|---|---|
Rituximab | Rituxin®/ Mabthera® | CD20 | Mouse Hybridoma | IgG1-kappa | Chimeric | 1997 | NHL; later CD20+CLL, FL, RA |
Transtuzumab | Herceptin® | HER-2 | Mouse Hybridoma | IgG1-kappa | Humanized | 1998 | HER-2+ MBC |
Alemtuzumab | Campath®/ Mabcampath® | CD52 | Rat Hybridoma | IgG1-kappa | Humanized | 2001 | CL L, T-cellLymphoma |
Ibritomomab tiuxitan | Zevalin® | CD20 | Mouse monoclonal | IgG1-kappa | Conjugated to Yittrium-90 | 2002 | NHL |
Tositumomab | Bexxar® | CD20 | Mouse monoclonal | IgG2a-lambda | Conjugated to I-131 | 2003 | NHL |
Cetuximab | Erbitux® | EGRF, HER-1 | Mouse monoclonal | IgG1- kappa | Chimeric | 2004 | EGRF+ MCC |
Bevacizumab | Avastin® | VEGF | Mouse monoclonal | IgG1- kappa | Humanized | 2004 | MCC |
Panitumumab | Vectibixâ„¢ | EGRF, HER-1 | Human monoclonal | IgG2-kappa | Human | 2006 | MCC |
Ofatumumab | Arzerraâ„¢ | CD20 | Human monoclonal | IgG1-kappa | Human | 2009 | Refractory CLL |
Ipilimumab | Yervoyâ„¢ | CTLA-4 | Human monoclonal | IgG1-kappa | Human | 2011 | MMel |
Pertuzumab | Perjetaâ„¢ | EGFR2, HER-2 | Mouse monoclonal | IgG1-kappa | Humanized | 2012 | BC |